6533b82cfe1ef96bd128ec90

RESEARCH PRODUCT

Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.

Michael A. KernChristoph W. MichalskiMartina MüllerWolfgang StremmelHelmut FriessHenning WalczakPeter H. KrammerHenning Schulze-bergkamenB. FleischerPeter SchirmacherAnke M. HauggKai BreuhahnTobias SchillingAndreas KochChristian Trautwein

subject

Cancer Researchmedicine.medical_specialtyProgrammed cell deathCarcinoma HepatocellularApoptosisMitochondria LiverBiologyTransfectionReceptors Tumor Necrosis FactorInternal medicineCell Line TumormedicineHumansfas ReceptorDeath domainInhibitor of apoptosis domainSulfonamidesCyclooxygenase 2 InhibitorsIntrinsic apoptosisLiver NeoplasmsFas receptorReceptors TNF-Related Apoptosis-Inducing LigandEndocrinologyOncologyUVB-induced apoptosisApoptosisCelecoxibCyclooxygenase 2Cancer researchPyrazolesSignal transductionSignal Transduction

description

AbstractInhibition of cyclooxygenase (COX)-2 elicits chemopreventive and therapeutic effects in solid tumors that are coupled with the induction of apoptosis in tumor cells. We investigated the mechanisms by which COX-2 inhibition induces apoptosis in hepatocellular carcinoma (HCC) cells. COX-2 inhibition triggered expression of the CD95, tumor necrosis factor (TNF)-R, and TNF-related apoptosis-inducing ligand (TRAIL)-R1 and TRAIL-R2 death receptors. Addition of the respective specific ligands further increased apoptosis, indicating that COX-2 inhibition induced the expression of functional death receptors. Overexpression of a dominant-negative Fas-associated death domain mutant reduced COX-2 inhibitor-mediated apoptosis. Furthermore, our findings showed a link between COX-2 inhibition and the mitochondrial apoptosis pathway. COX-2 inhibition led to a rapid down-regulation of myeloid cell leukemia-1 (Mcl-1), an antiapoptotic member of the Bcl-2 family, followed by translocation of Bax to mitochondria and cytochrome c release from mitochondria. Consequently, overexpression of Mcl-1 led to inhibition of COX-2 inhibitor-mediated apoptosis. Furthermore, blocking endogenous Mcl-1 function using a small-interfering RNA approach enhanced COX-2 inhibitor-mediated apoptosis. It is of clinical importance that celecoxib acted synergistically with chemotherapeutic drugs in the induction of apoptosis in HCC cells. The clinical relevance of these results is further substantiated by the finding that COX-2 inhibitors did not sensitize primary human hepatocytes toward chemotherapy-induced apoptosis. In conclusion, COX-2 inhibition engages different apoptosis pathways in HCC cells stimulating death receptor signaling, activation of caspases, and apoptosis originating from mitochondria. (Cancer Res 2006; 66(14): 7059-66)

10.1158/0008-5472.can-06-0325https://pubmed.ncbi.nlm.nih.gov/17545641